ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
Therapeutics
4.78
+0.1100
2.36%
盘后:
4.87
0.0900
+1.88%
19:33 EDT
成交量:
54.51万
成交额:
259.22万
市值:
1.50亿
市盈率:
-1.16
高:
4.84
开:
4.67
低:
4.58
收:
4.67
52周最高:
50.40
52周最低:
4.54
股本:
3,129.00万
流通股本:
1,839.33万
量比:
1.02
换手率:
2.96%
股息:
- -
股息率:
- -
每股收益(TTM):
-4.1300
每股收益(LYR):
-2.8503
净资产收益率:
-59.21%
总资产收益率:
-37.36%
市净率:
0.68
市盈率(LYR):
-1.68
数据加载中...
总览
公司
新闻资讯
公告
生物科技公司Capricor Therapeutics面临FDA质疑与证券欺诈调查 股价连续暴跌
环球市场播报
·
07/28
堡垒生物技术及其子公司优瑞卡治疗宣布,Crystalys Therapeutics完成1.3亿美元B轮融资
投资观察
·
07/27
美股异动 | CRISPR基因编辑公司Scribe Therapeutics(SCTX.US)登陆美股市场 开盘后涨超59%
智通财经
·
07/24
Summit Therapeutics美股盘前跌超11%
每日经济新闻
·
07/22
小分子抗癌疗法开发商BlossomHill Therapeutics(BLSM.US)申请美股上市 拟筹资至多1亿美元
智通财经
·
07/20
缺氧疗法生物科技公司NuvOx Therapeutics(NUOX.US)申请美股IPO,拟募资2000万美元
智通财经
·
07/20
新闻稿:Glucotrack与Lōkahi Therapeutics完成战略业务合并,建立Lōkahi控制的公开平台
投资观察
·
07/15
信达生物与 Spero Therapeutics就IBI355(第三代抗CD40L单抗,临床II期准备阶段)达成独家许可协议
美通社
·
07/14
Stoke Therapeutics任命Thomas McCauley博士为首席科学官
环球市场播报
·
07/13
Pliant Therapeutics任命Flavia Borellini博士和Robert Iannone博士加入董事会
投资观察
·
07/13
Cardiol Therapeutics将出席B. Riley Mind, Muscle & Vision峰会炉边谈话
环球市场播报
·
07/09
云顶新耀宣布完成与Travere Therapeutics关于希布替尼(EVER001)的独家授权许可与合作协议交割
美通社
·
07/07
Incyte(INCY)以12.5亿美元完成收购Vega Therapeutics 拓宽血液学管线布局
金吾财讯
·
07/06
Lenz Therapeutics推出新型远程医疗处方方案,加速老花眼患者获取Vizz®治疗
美股速递
·
07/06
生物技术公司Scribe Therapeutics(SCTX.US)申请美股IPO 拟筹资至多7500万美元
智通财经
·
07/06
联合治疗公司以1.4亿美元现金收购生物技术公司Thymmune Therapeutics。
格隆汇
·
07/02
Stoke Therapeutics完成Dravet综合征药物关键III期试验患者入组
环球市场播报
·
06/30
Unicycive Therapeutics股价下跌45.8%,此前美国食品药品监督管理局拒绝批准该公司的肾病药物。
智通财经
·
06/30
新闻稿:Akari Therapeutics 完成先前宣布的PIPE融资,强化资产负债表以迎接关键临床与监管里程碑
投资观察
·
06/29
新闻稿:Rani Therapeutics任命尼古拉斯·马埃斯塔斯为首席财务官
投资观察
·
06/29
更多
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.etasphere.com/hans/stock/LENZ/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":4.78,"timestamp":1787774400000,"preClose":4.67,"halted":0,"volume":545051,"hourTrading":{"tag":"盘后","latestPrice":4.87,"preClose":4.78,"latestTime":"19:33 EDT","volume":3633,"amount":17401.86,"timestamp":1787787238297,"change":0.09,"changeRate":0.018828,"amplitude":0.037657},"delay":0,"changeRate":0.023554603854389792,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"未开盘","change":0.11,"latestTime":"08-26 16:00:00 EDT","open":4.67,"high":4.84,"low":4.58,"amount":2592171.8595136,"amplitude":0.055675,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787817600000},"marketStatusCode":0,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":4.67,"preHourTrading":{"tag":"盘前","latestPrice":4.67,"preClose":4.67,"latestTime":"08:48 EDT","volume":5019,"amount":23718.338490000002,"timestamp":1787748533984,"change":0,"changeRate":0,"amplitude":0.025503},"postHourTrading":{"tag":"盘后","latestPrice":4.87,"preClose":4.78,"latestTime":"19:33 EDT","volume":3633,"amount":17401.86,"timestamp":1787787238297,"change":0.09,"changeRate":0.018828,"amplitude":0.037657},"volumeRatio":1.022038,"impliedVol":3.0968,"impliedVolPercentile":0.9681},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":18393300,"roa":"-37.36%","roe":"-59.21%","lyrEps":-2.850329,"volumeRatio":1.022038,"shares":31289969,"dividePrice":0,"high":4.84,"amplitude":0.055675,"preClose":4.67,"low":4.58,"week52Low":4.535,"pbRate":"0.68","psRate":"6.96","week52High":50.4,"institutionHeld":0,"latestPrice":4.78,"eps":-4.13,"divideRate":0,"volume":545051,"delay":0,"ttmEps":-4.13,"open":4.67,"prevYearClose":16,"prevWeekClose":4.68,"prevMonthClose":5.3,"prevQuarterClose":5.68,"fiveDayClose":4.92,"twentyDayClose":5.72,"sixtyDayClose":7.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LENZ","fiscalQuarterEnding":"2026/06","expectedEps":-1.21,"name":null,"time":"盘后","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-1.02},{"market":"US","date":"2026-05-11","symbol":"LENZ","fiscalQuarterEnding":"2026/03","expectedEps":-1.1,"name":null,"time":"盘后","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"盘前","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"盘前","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.2857,"hold":0.2857,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-08-25","current":-1.157385,"percent":1,"low":-26.69966,"twenty":-16.308294,"median":-9.84549,"eighty":-5.431761,"high":-1.14458,"avg":-10.693185,"sd":6.122868,"marketCap":144219374},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282},{"date":"2026-04-02","current":-3.569637,"twenty":-16.958959,"median":-11.220775,"eighty":-7.447644,"marketCap":293163583},{"date":"2026-04-10","current":-3.54673,"twenty":-16.933679,"median":-11.193196,"eighty":-7.269441,"marketCap":291282320},{"date":"2026-04-17","current":-3.680353,"twenty":-16.916201,"median":-11.141188,"eighty":-7.181235,"marketCap":302256358},{"date":"2026-04-24","current":-3.493281,"twenty":-16.878888,"median":-11.077981,"eighty":-6.952736,"marketCap":286892705},{"date":"2026-05-01","current":-3.428379,"twenty":-16.817122,"median":-11.044571,"eighty":-6.825202,"marketCap":281562458},{"date":"2026-05-08","current":-3.710895,"twenty":-16.761494,"median":-10.861657,"eighty":-6.578636,"marketCap":304764709},{"date":"2026-05-15","current":-2.097082,"twenty":-16.730518,"median":-10.778852,"eighty":-6.457565,"marketCap":228573532},{"date":"2026-05-22","current":-2.163245,"twenty":-16.709792,"median":-10.723495,"eighty":-6.429023,"marketCap":235785042},{"date":"2026-05-29","current":-2.298448,"twenty":-16.694346,"median":-10.694071,"eighty":-6.404339,"marketCap":250521608},{"date":"2026-06-05","current":-2.071192,"twenty":-16.632408,"median":-10.560046,"eighty":-6.370576,"marketCap":225751636},{"date":"2026-06-12","current":-1.869826,"twenty":-16.608825,"median":-10.439663,"eighty":-6.329861,"marketCap":203803561},{"date":"2026-06-18","current":-1.8238,"twenty":-16.599392,"median":-10.388191,"eighty":-6.238545,"marketCap":198786857},{"date":"2026-06-26","current":-1.585037,"twenty":-16.591349,"median":-10.356288,"eighty":-6.201347,"marketCap":172762710},{"date":"2026-07-02","current":-1.665584,"twenty":-16.562409,"median":-10.323331,"eighty":-6.136275,"marketCap":181541941},{"date":"2026-07-10","current":-1.665584,"twenty":-16.458857,"median":-10.297741,"eighty":-6.098214,"marketCap":181541941},{"date":"2026-07-17","current":-1.403808,"twenty":-16.42504,"median":-10.207556,"eighty":-5.994366,"marketCap":153009442},{"date":"2026-07-24","current":-1.452711,"twenty":-16.399781,"median":-10.175633,"eighty":-5.904593,"marketCap":158339689},{"date":"2026-07-31","current":-1.656954,"twenty":-16.359791,"median":-10.130408,"eighty":-5.831073,"marketCap":180601309},{"date":"2026-08-07","current":-1.501614,"twenty":-16.336075,"median":-10.052902,"eighty":-5.780516,"marketCap":163669936},{"date":"2026-08-14","current":-1.147074,"twenty":-16.332656,"median":-9.910465,"eighty":-5.64279,"marketCap":144533577},{"date":"2026-08-21","current":-1.162036,"twenty":-16.31728,"median":-9.875604,"eighty":-5.484249,"marketCap":146418798},{"date":"2026-08-25","current":-1.14458,"twenty":-16.308294,"median":-9.84549,"eighty":-5.431761,"marketCap":144219374}],"updateTime":1787792834867},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654885615","title":"生物科技公司Capricor Therapeutics面临FDA质疑与证券欺诈调查 股价连续暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2654885615","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654885615?lang=zh_cn&edition=fundamental","pubTime":"2026-07-28 23:15","pubTimestamp":1785251700,"startTime":"0","endTime":"0","summary":"生物科技公司Capricor Therapeutics正面临严峻挑战,其股价近期大幅下挫——周一该股收盘重挫64.49%,周二早盘再跌逾15%。FDA审查人员对Capricor的核心候选药物deramiocel的疗效数据提出质疑,认为其关键性III期HOPE-3试验未能达到预设的主要和关键次要疗效终点。此外,多家律师事务所已对Capricor提起或正在调查证券欺诈集体诉讼。诉讼主要指控公司在2024年10月9日至2025年7月10日期间,就其获得FDA批准的可能性作出了虚假和误导性陈述,同时隐瞒了关于deramiocel安全性和有效性的不利事实。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-28/doc-inikksxz1845469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161027","IBBJ","BK4007","LNGR","IEIH","LENZ","SYNB","BK4588","159837","GDOC","BK4585","XBI","AGNG","LABU","HBImain","MEDX","BK4539","BK4139","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128927873","title":"堡垒生物技术及其子公司优瑞卡治疗宣布,Crystalys Therapeutics完成1.3亿美元B轮融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1128927873","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128927873?lang=zh_cn&edition=fundamental","pubTime":"2026-07-27 20:02","pubTimestamp":1785153766,"startTime":"0","endTime":"0","summary":"迈阿密,2026年7月27日——优瑞卡治疗公司作为Fortress Biotech, Inc.的子公司,今日宣布,Crystalys Therapeutics, Inc.已超额完成1.3亿美元的B轮融资。优瑞卡在Crystalys中持有股权,这笔资金将用于支持dotinurad的全球晚期临床开发及商业化筹备工作。Dotinurad是一种新一代、每日一次口服的URAT1抑制剂,专用于治疗痛风。Crystalys于2024年从优瑞卡收购了dotinurad,目前优瑞卡持有Crystalys的少数股权,并有资格获得未来dotinurad净销售额3%的特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","LENZ","BK4581","HELS","BK4585","XBI","FBIO","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654036699","title":"美股异动 | CRISPR基因编辑公司Scribe Therapeutics(SCTX.US)登陆美股市场 开盘后涨超59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654036699","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654036699?lang=zh_cn&edition=fundamental","pubTime":"2026-07-24 23:57","pubTimestamp":1784908651,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","HELX","FWD","LU1861558580.USD","SYNB","LU1861559042.SGD","CRSP","ARKG","XT","BK4611","BK4556","BK4139","LENZ","IDNA","NBDS","BK4539","GNOM","KOMP","TARK","DTEC","SCTX","BK4585","BK4588","BMED","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653751229","title":"Summit Therapeutics美股盘前跌超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653751229","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653751229?lang=zh_cn&edition=fundamental","pubTime":"2026-07-22 18:36","pubTimestamp":1784716593,"startTime":"0","endTime":"0","summary":"Summit Therapeutics美股盘前跌超11%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817433621.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817433621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LENZ","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652298740","title":"小分子抗癌疗法开发商BlossomHill Therapeutics(BLSM.US)申请美股上市 拟筹资至多1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652298740","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652298740?lang=zh_cn&edition=fundamental","pubTime":"2026-07-20 15:20","pubTimestamp":1784532012,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,BlossomHill Therapeutics是一家管线已推进至二期临床阶段的生物技术企业,专注于开发小分子抗癌疗法。该公司于上周五向美国证券交易委员会递交招股书,拟通过首次公开募股募资至多1亿美元。BlossomHill Therapeutics专注研发小分子抗癌药物:先找出现有疗法的结构缺陷,再设计新的化合物来克服这些缺陷。BlossomHill Therapeutics于2026年4月24日秘密提交了上市申请。摩根大通、Leerink Partners、Guggenheim Securities、LifeSci Capital和HC Wainwright是此次交易的联合承销商。定价条款未披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4539","LENZ","IPOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652298685","title":"缺氧疗法生物科技公司NuvOx Therapeutics(NUOX.US)申请美股IPO,拟募资2000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652298685","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652298685?lang=zh_cn&edition=fundamental","pubTime":"2026-07-20 14:55","pubTimestamp":1784530507,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","KCE","BK4127","IPOS","AGNG","BK4581","MEDX","BK4539","SYNB","FRHC","BK4585","XBI","LENZ","BK4007","BK4139","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182696709","title":"新闻稿:Glucotrack与Lōkahi Therapeutics完成战略业务合并,建立Lōkahi控制的公开平台","url":"https://stock-news.laohu8.com/highlight/detail?id=1182696709","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182696709?lang=zh_cn&edition=fundamental","pubTime":"2026-07-15 05:45","pubTimestamp":1784065528,"startTime":"0","endTime":"0","summary":"Glucotrack, Inc.今日宣布,其与Lōkahi Therapeutics的战略业务合并已正式完成。本次交易的结构设计使得Lōkahi Therapeutics成为合并后公司的运营及控制主体,并利用Glucotrack的公开市场平台来支持长期增长及资本获取。在交易完成之际,Lōkahi Therapeutics的证券持有人获得了Glucotrack普通股与可转换优先股的组合。届时,在完全稀释基础上,并受交易相关融资及常规调整影响,Lōkahi Therapeutics的证券持有人将持有合并后公司约90%的股份。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GCTK","BK4139","BK4007","BK4082","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651174232","title":"信达生物与 Spero Therapeutics就IBI355(第三代抗CD40L单抗,临床II期准备阶段)达成独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2651174232","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651174232?lang=zh_cn&edition=fundamental","pubTime":"2026-07-14 18:00","pubTimestamp":1784023200,"startTime":"0","endTime":"0","summary":"Spero计划于2027年第二季度启动IBI355治疗IgG4-RD患者的临床II期研究;信达生物计划于2027年初前在中国启动IBI355治疗SjD的临床II期研究。我们非常高兴与Spero Therapeutics达成合作,共同推进IBI355的全球开发。结合信达生物和Spero Therapeutics在自身免疫领域的临床资源和专注投入,我们将共同加速这一差异化疗法的研发进程,致力于为慢性病患者带来新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5003988_ZH03988_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5003988_ZH03988_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","LENZ","01801","BK1589","LU2242644610.SGD","LU2488822045.USD","BK1583","LU2097828805.USD","LU0455707207.USD","BK4007","HK0000165453.HKD","BK4539","LU2097828631.EUR","LU0502904849.HKD","LU2328871848.SGD","LU2097828474.EUR","BK4139","LU2097828557.USD","LU1969619763.USD","KURE","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651722111","title":"Stoke Therapeutics任命Thomas McCauley博士为首席科学官","url":"https://stock-news.laohu8.com/highlight/detail?id=2651722111","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651722111?lang=zh_cn&edition=fundamental","pubTime":"2026-07-13 20:49","pubTimestamp":1783946940,"startTime":"0","endTime":"0","summary":"生物技术公司Stoke Therapeutics近日宣布,任命Thomas McCauley博士为首席科学官,负责领导公司的科学战略,并推动其基于RNA药物平台的管线扩展与临床推进。他曾担任Neptune Bio的总裁兼首席执行官,并先后在Omega Therapeutics、Macrolide Pharmaceuticals和Translate Bio担任首席科学官。 Stoke Therapeutics专注于利用其专有的TANGO技术开发反义寡核苷酸药物,以选择性恢复蛋白质水平。Stoke与渤健已就此药物建立战略合作,共同进行开发和商业化。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-13/doc-inihsisy8947593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183275253","title":"Pliant Therapeutics任命Flavia Borellini博士和Robert Iannone博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1183275253","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183275253?lang=zh_cn&edition=fundamental","pubTime":"2026-07-13 20:35","pubTimestamp":1783946106,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司Pliant Therapeutics今日宣布,任命Flavia Borellini博士与Robert Iannone博士为公司董事会新成员。这两项任命为董事会注入了深厚的全球肿瘤药物开发经验,并进一步强化了其在运营与监管事务方面的专业能力。目前,除了在Pliant任职外,他还担任Autolus Therapeutics的董事会成员。关于Pliant Therapeutics, Inc.:Pliant Therapeutics是一家临床阶段的生物制药公司,专注于基于整合素的疗法的发现与开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","BK4539","BK4022","BK4585","BK4139","R","BK4007","LENZ","BK4588","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650924739","title":"Cardiol Therapeutics将出席B. Riley Mind, Muscle & Vision峰会炉边谈话","url":"https://stock-news.laohu8.com/highlight/detail?id=2650924739","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650924739?lang=zh_cn&edition=fundamental","pubTime":"2026-07-09 20:54","pubTimestamp":1783601672,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics Inc.宣布,将参加于2026年7月16日在波士顿举行的B. Riley Securities Mind, Muscle & Vision Summit,并在当日下午12:20进行炉边谈话。 此次峰会为B. Riley Securities主办的单一医疗健康会议,聚焦神经学、肌肉及眼科疾病领域的创新成果。 Cardiol Therapeutics是一家处于后期阶段的生命科学公司,专注于推进心脏疾病抗炎和抗纤维化疗法的开发。 Cardiol目前正在推进MAVERIC项目,评估CardiolRx治疗复发性心包炎的疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-09/doc-inihfihx8573744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4139","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649935543","title":"云顶新耀宣布完成与Travere Therapeutics关于希布替尼(EVER001)的独家授权许可与合作协议交割","url":"https://stock-news.laohu8.com/highlight/detail?id=2649935543","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649935543?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 18:13","pubTimestamp":1783419180,"startTime":"0","endTime":"0","summary":"上海2026年7月7日 /美通社/ -- 云顶新耀是一家专注于创新药研发、临床开发、制造及商业化的生物制药公司,今日宣布,已根据协议条款完成与Travere Therapeutics, Inc.关于EVER001的独家授权许可与合作协议交割,表明该交易已满足必要监管程序等约定交割条件,充分体现了公司承诺兑现的执行能力。双方合作将正式进入实施阶段,并将共同推进EVER001的后续开发与商业化。根据协议,Travere Therapeutics将获得EVER001除大中华区及部分东南亚国家以外区域的独家开发及商业化权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4999306_ZH99306_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4999306_ZH99306_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1583","01952","FFTY","BK1161","BK1574","BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649858622","title":"Incyte(INCY)以12.5亿美元完成收购Vega Therapeutics 拓宽血液学管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2649858622","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649858622?lang=zh_cn&edition=fundamental","pubTime":"2026-07-06 21:19","pubTimestamp":1783343950,"startTime":"0","endTime":"0","summary":"根据双方此前达成的股票购买协议,Incyte已支付12.5亿美元的预付款,收购了Vega Therapeutics的全部发行在外股份。此外,Star Therapeutics未来还有权获得最高达7.5亿美元的商业销售里程碑付款。通过本次收购,Incyte成功将Vega的核心资产——创新单克隆抗体VGA039收入囊中。目前,该药物正在全球开展一项名为VIVID-6的单臂交叉3期临床试验,以评估其在各类血管性血友病患者中的安全性和有效性。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302236","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4532","BK4139","IDNA","BK4007","LENZ","BK4588","INCY","BK4585","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183410479","title":"Lenz Therapeutics推出新型远程医疗处方方案,加速老花眼患者获取Vizz®治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1183410479","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183410479?lang=zh_cn&edition=fundamental","pubTime":"2026-07-06 20:22","pubTimestamp":1783340531,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics宣布推出一种新型远程医疗处方方案,旨在加速老花眼患者获取Vizz®治疗。此举将简化患者的治疗流程,提高治疗的可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649197641","title":"生物技术公司Scribe Therapeutics(SCTX.US)申请美股IPO 拟筹资至多7500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649197641","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649197641?lang=zh_cn&edition=fundamental","pubTime":"2026-07-06 15:30","pubTimestamp":1783323045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","HELX","FRHC","BK4127","KCE","WDNA","IPOS","LENZ","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648509782","title":"联合治疗公司以1.4亿美元现金收购生物技术公司Thymmune Therapeutics。","url":"https://stock-news.laohu8.com/highlight/detail?id=2648509782","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648509782?lang=zh_cn&edition=fundamental","pubTime":"2026-07-02 18:31","pubTimestamp":1782988300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LENZ","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647551730","title":"Stoke Therapeutics完成Dravet综合征药物关键III期试验患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2647551730","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647551730?lang=zh_cn&edition=fundamental","pubTime":"2026-06-30 21:47","pubTimestamp":1782827220,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics近日宣布,其针对Dravet综合征的潜在疾病修饰疗法zorevunersen的全球III期EMPEROR研究已完成全部162名患者的入组工作。这一里程碑的达成,标志着该药物向提交新药申请、尽快惠及患者迈出了关键一步。 此前,公司预计将在2026年第二季度完成约150名患者的入组。此次公布的162名患者入组数量超出了这一预期。 Zorevunersen是一款首创的反义寡核苷酸药物,旨在通过增加脑细胞中非突变SCN1A基因拷贝的功能性NaV1.1蛋白表达,从根本上治疗Dravet综合征。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-30/doc-iniffcps6559776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","BK4539","LENZ","III","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647455165","title":"Unicycive Therapeutics股价下跌45.8%,此前美国食品药品监督管理局拒绝批准该公司的肾病药物。","url":"https://stock-news.laohu8.com/highlight/detail?id=2647455165","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647455165?lang=zh_cn&edition=fundamental","pubTime":"2026-06-30 21:31","pubTimestamp":1782826311,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["UNCY","BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132616293","title":"新闻稿:Akari Therapeutics 完成先前宣布的PIPE融资,强化资产负债表以迎接关键临床与监管里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1132616293","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132616293?lang=zh_cn&edition=fundamental","pubTime":"2026-06-29 20:47","pubTimestamp":1782737248,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC 是一家专注于开发搭载新型RNA剪接调节剂有效载荷的抗体药物偶联物的肿瘤学生物技术公司。该公司近日宣布,已通过将剩余计划投资交割合并为单一融资事件,完成了先前公布的私募股权投资。结合五月份完成的认股权证行权,公司在2026年第二季度总计获得了约830万美元资本。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","LENZ","AKTX","PIPE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146816793","title":"新闻稿:Rani Therapeutics任命尼古拉斯·马埃斯塔斯为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1146816793","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146816793?lang=zh_cn&edition=fundamental","pubTime":"2026-06-29 20:02","pubTimestamp":1782734563,"startTime":"0","endTime":"0","summary":"临床阶段生物治疗公司Rani Therapeutics Holdings, Inc.今日宣布,任命尼古拉斯·马埃斯塔斯为首席财务官,即刻生效。Rani Therapeutics首席执行官塔拉特·伊姆兰表示:“我们很高兴欢迎尼古拉斯担任我们的新任首席财务官。他在生物制药资本市场和企业战略方面的深厚经验,使其非常适合引领Rani进入下一个发展阶段。同时,我们也要再次感谢斯瓦伊·桑福德多年来的稳健领导及其为保障平稳交接所做的承诺。”","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LENZ","R","BK4022","BK4539","BK4232"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":111,"code":"91000000","status":"200"}]}}